Overview
- Neurotronics, a Nihon Kohden company, has received FDA 510(k) clearance for its Sleep Analysis Module (SAM), a software-only medical device designed to estimate total sleep time (TST).
- The AI/ML-based algorithm analyses photoplethysmography (PPG) signals already collected by pulse oximeters to estimate how long a patient sleeps, without requiring additional sensors or changes to the patient setup.
- SAM will initially be integrated into Neurotronics’ Polysmith sleep diagnostic software for analysing studies recorded through its NomadAir home sleep apnea testing (HSAT) solution.
- The clearance marks Neurotronics’ first FDA-cleared AI/ML-based sleep analysis algorithm and establishes a foundation for further software-driven diagnostic innovations.
The News
Neurotronics, a Nihon Kohden company, has received FDA 510(k) clearance for its Sleep Analysis Module (SAM), introducing an AI/ML-based approach to estimating total sleep time using physiological signals already collected during sleep studies. The software-only medical device is designed to provide healthcare professionals with additional information when evaluating sleep disorders, particularly obstructive sleep apnea (OSA).
The technology addresses a limitation in many home sleep apnea tests. Respiratory events are generally assessed in relation to the amount of time a patient spends asleep. However, because measuring sleep duration traditionally requires additional signals such as electroencephalography (EEG), electrooculography (EOG), and electromyography (EMG), many home sleep studies use total recording time instead of actual sleep time.
SAM takes a different approach by analysing photoplethysmography (PPG) signals already captured by a pulse oximeter. Using an AI/ML-based algorithm, the software estimates total sleep time without requiring additional sensors or modifications to the patient’s existing testing setup.
This distinction can influence the assessment of OSA severity. The apnea-hypopnea index (AHI), which measures the frequency of apnea and hypopnea events, is calculated relative to sleep time. When total recording time is used instead, periods during which a patient is awake may also be included in the calculation, potentially affecting the estimated severity of the condition. By providing an estimate of actual sleep duration, SAM offers clinicians additional information for interpreting home sleep study results.
Neurotronics will initially integrate SAM into its Polysmith sleep diagnostic software for analysing studies recorded through the NomadAir home sleep apnea testing solution. This allows clinicians to use estimated sleep time rather than relying exclusively on total recording time when evaluating compatible home sleep studies.
The FDA clearance represents several milestones for the company. SAM is Neurotronics’ first FDA-cleared AI/ML-based sleep analysis algorithm, demonstrates how existing physiological signals can support additional clinical insights, and establishes a software-based foundation that could extend advanced sleep analysis capabilities across compatible products and platforms.
Neurotronics is currently completing the integration and verification activities required before commercial release.
Industry Perspective
The adoption of AI/ML in sleep diagnostics is creating opportunities to extract more clinical information from physiological signals already collected during routine testing. This is particularly relevant to home sleep apnea testing, where simplifying equipment requirements can make diagnostic procedures more convenient for patients.
Estimating sleep duration from PPG signals could help address some limitations associated with using total recording time when interpreting respiratory events. However, algorithm-derived estimates must be evaluated within their intended clinical context, as they do not replace comprehensive sleep monitoring or full sleep staging.
Strategic Impact
For Neurotronics, FDA clearance of SAM strengthens its position in software-driven sleep diagnostics and expands its capabilities beyond traditional hardware-based monitoring systems. Its initial integration with Polysmith and NomadAir also provides a route to introduce the technology within the company’s existing sleep diagnostic ecosystem.
For Nihon Kohden, the development highlights an opportunity to incorporate AI/ML capabilities into established medical device workflows, potentially improving the clinical utility of existing monitoring technologies without increasing hardware complexity.
Source: Businesswire
